Search

Your search keyword '"Veluchamy, John P."' showing total 10 results
Start Over Author "Veluchamy, John P."
10 results on '"Veluchamy, John P."'

3. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

Author

de Bruin, Renée C. G., primary, Veluchamy, John P., additional, Lougheed, Sinéad M., additional, Schneiders, Famke L., additional, Lopez-Lastra, Silvia, additional, Lameris, Roeland, additional, Stam, Anita G., additional, Sebestyen, Zsolt, additional, Kuball, Jürgen, additional, Molthoff, Carla F. M., additional, Hooijberg, Erik, additional, Roovers, Rob C., additional, Santo, James P. Di, additional, van Bergen en Henegouwen, Paul M. P., additional, Verheul, Henk M. W., additional, de Gruijl, Tanja D., additional, and van der Vliet, Hans J., additional

Published
2017
Full Text
View/download PDF

7. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status

Author

Veluchamy, John P., primary, Heeren, A. Marijne, additional, Spanholtz, Jan, additional, van Eendenburg, Jaap D. H., additional, Heideman, Daniëlle A. M., additional, Kenter, Gemma G., additional, Verheul, Henk M., additional, van der Vliet, Hans J., additional, Jordanova, Ekaterina S., additional, and de Gruijl, Tanja D., additional

Published
2016
Full Text
View/download PDF

8. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells

Author

Grimaldi, Francesco, Potter, Victoria, Perez-Abellan, Pilar, Veluchamy, John P., Atif, Muhammad, Grain, Rosemary, Sen, Monica, Best, Steven, Lea, Nicholas, Rice, Carmel, Pagliuca, Antonio, Mufti, Ghulam J., Marsh, Judith C.W., and Barber, Linda D.

Subjects
Adult, Male, Transplantation Conditioning, Adolescent, aplastic anemia, Cell Survival, education, T cells, Hematopoietic stem cell transplantation, CD8-Positive T-Lymphocytes, Chimerism, Article, Young Adult, T-Lymphocyte Subsets, alemtuzumab, Humans, Alemtuzumab, Retrospective Studies, Transplantation, Transplantation Chimera, Graft Survival, Anemia, Aplastic, Hematology, Middle Aged, humanities, Treatment Outcome, surgical procedures, operative, chimerism, hematopoietic stem cell transplantation, Female, Aplastic anemia, Immunosuppressive Agents, Whole-Body Irradiation
Abstract

Highlights • Clinical outcomes are excellent using an alemtuzumab-containing hematopoietic stem cell transplantation regimen for aplastic anemia. • Outcomes are excellent despite prolonged abnormality of the T cell profile. • Recipient-derived CD8 T cells shape persistent mixed chimerism., Prevention of graft-versus-host disease (GVHD) is paramount for allogeneic hematopoietic stem cell transplantation (HSCT) to treat nonmalignant diseases. We previously reported that allogeneic HSCT for severe aplastic anemia (SAA) using the fludarabine, cyclophosphamide, and alemtuzumab (Campath-1H) (FCC) regimen is associated with a very low risk of GVHD and excellent clinical outcomes. We now report a single-center study of 45 patients with longer follow-up and investigation of lymphocyte recovery. Overall survival (OS) was 93%, and event-free survival (EFS) was 90.7%. Acute and chronic GVHD each occurred in 6 patients (13.3%), and only 1 case was severe. Mixed T cell chimerism was frequent and persisted after cessation of immunosuppression. T cells were extensively depleted, representing only 11.3% of lymphocytes at day 30 and rising to 43.8% by 1 year, but still significantly below normal levels (67.2%; P = .018), and deficiency persisted after immunosuppressive therapy (IST) withdrawal. Depletion of CD4 T cells was particularly profound, causing inversion of the normal CD4:CD8 T cell ratio. T cell subset composition was also abnormal, with memory and effector T cells predominating for at least 6 months after FCC HSCT. Analysis of T cell subset chimerism showed that CD4 T cells were predominantly donor-derived at 1 year, whereas recipient-derived CD8 T cells shaped mixed chimerism with a notable contribution of recipient effector CD8 T cells. The prolonged mixed T cell chimerism after IST withdrawal and low incidence of GVHD indicates the establishment of mutual tolerance, but the low incidence of viral disease suggests maintenance of antiviral immunity. Our study shows that despite the abnormal T cell profile after allogeneic HSCT for SAA using the FCC regimen, this regimen is conducive to an excellent clinical outcome.

Full Text
View/download PDF

9. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

Author

de Bruin, Renée C. G., Veluchamy, John P., Lougheed, Sinéad M., Schneiders, Famke L., Lopez-Lastra, Silvia, Lameris, Roeland, Stam, Anita G., Sebestyen, Zsolt, Kuball, Jürgen, Molthoff, Carla F. M., Hooijberg, Erik, Roovers, Rob C., Santo, James P. Di, van Bergen en Henegouwen, Paul M. P., Verheul, Henk M. W., de Gruijl, Tanja D., and van der Vliet, Hans J.

Subjects
*CANCER immunotherapy, *T cells, *CANCER treatment, *THERAPEUTICS
Abstract

Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy. Vγ9Vδ2-T cell-based cancer immunotherapeutic approaches developed so far have been generally well tolerated and were able to induce significant clinical responses. However, overall results were inconsistent, possibly due to the fact that these strategies induced systemic activation of Vγ9Vδ2-T cells without preferential accumulation and targeted activation in the tumor. Here we show that a novel bispecific nanobody-based construct targeting both Vγ9Vδ2-T cells and EGFR induced potent Vγ9Vδ2-T cell activation and subsequent tumor cell lysis bothin vitroand in anin vivomouse xenograft model. Tumor cell lysis was independent ofKRASandBRAFtumor mutation status and common Vγ9Vδ2-T cell receptor sequence variations. In combination with the conserved monomorphic nature of the Vγ9Vδ2-TCR and the facile replacement of the tumor-specific nanobody, this immunotherapeutic approach can be applied to a large group of cancer patients. [ABSTRACT FROM PUBLISHER]

Published
2018
Full Text
View/download PDF

10. Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease

Author

Grimaldi, Francesco, Perez-Abellan, Pilar, Best, Steven, Lea, Nicholas, Veluchamy, John, Atif, Muhammad, Grain, Rosemary, Sen, Monica, Kulasekararaj, Austin G., Pagliuca, Antonio, Potter, Victoria T, Mufti, Ghulam J, Marsh, Judith C.W., and Barber, Linda D

Abstract

Mixed T-cell chimerism is frequent and persists despite discontinuation of immunosuppression after hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA) using the fludarabine, cyclophosphamide and alemtuzumab/campath (FCC) conditioning regimen. To investigate the basis for long-term co-existence of donor and patient T cells and remarkably low rates of graft versus host disease (GVHD), the lymphocyte composition and lymphocyte subset chimerism of adult patients transplanted for SAA using FCC was assessed.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results